[{"Assets_0_Q2_USD":170185000.0,"CommonStockSharesOutstanding_0_Q2_shares":270792058.0,"EarningsPerShareBasic_1_Q2_USD":-0.05,"EarningsPerShareBasic_2_Q2_USD":-0.13,"EarningsPerShareDiluted_1_Q2_USD":-0.05,"EarningsPerShareDiluted_2_Q2_USD":-0.13,"NetIncomeLoss_1_Q2_USD":-13634000.0,"NetIncomeLoss_2_Q2_USD":-34575000.0,"StockholdersEquity_0_Q2_USD":-38764000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":270725000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":270445000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":270725000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":270445000.0,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170802"}]